Excelra Knowledge Solutions (formerly GVK Informatics) is a leading Informatics Solutions company that leverages its extensive scientific knowledge base, technology and relevant domain expertise to provide intelligent data and analytics solutions to customers globally. Excelra's expertise span across Data Solutions, Data Indexing & Abstraction and Data Analytics. The company has over nine successful Drug Repurposing collaborations with leading pharmaceutical companies and has developed a proprietary Drug Repurposing Platform and Computational Biology capabilities. Excelra has a team of 650+ scientists with rich experience in Chemistry, Biology and Clinical Sciences who are engaged in curation of databases spanning SAR (GOSTAR), Biomarkers (GOBIOM) and Clinical outcomes. These databases are considered as industry standards and numerous publications have been made using the underlying content. Excelra also supports the lifescience community through its cutting edge analytics group by providing drug repurposing, computational biology, biomarker identification, HEOR and RWE services. Excelra's portfolio of customers include some of the world's largest Pharmaceutical, Biotechnology, Publishing, Agrochemical, Life Sciences and Academic institutions in the USA, EU, Japan and Asia Pacific.
Customized data annotation service from literature (public/proprietary):
SAR data annotation from patents/journals and other documents
Biomarker data annotation
Competitive landscape report generation
Gene/Variant data annotation
Pre-clinical safety/toxicity data annotation
Excelra Clinical Outcomes Databases contain the summary level data of the Dosage, Demographic, Pk/PD, trial design etc. of all drugs treated for a particular indication. Our databases have formed the basis of regulatory submissions where Meta-Analysis (for instance) has been used. The databases provide readily available information on:
Biomarker database (GOBIOM)
Excelra Biomarker database (GOBIOM) is a collection of 125,000 biomarkers (Clinically evaluated, Exploratory and Pre-clinical) for >2,500 indications reported in global clinical trials, published literature and scientific conferences across 18 different therapeutic areas. It comes with a user friendly, VeriSign certified interface with built-in analysis tools to perform the statistical analysis.
GOBIOM contains quickly accessible information on:
Biomarker details and Efficacy and Safety characteristics
Drug-Induced organ toxicities
FDA/EMEA approval data for biomarkers and associated assay methodologies
Analytical and Clinical qualification
Drugs/Intervention details Endpoints observed
Clinical and Preclinical qualification Coverage of Study population and much more details
Small molecule SAR database (GOSTAR)
Excelra's small molecule SAR database is a repository of 7 million small molecules with 23 million associated SAR data points for about 9,300 unique targets. The database contains information on SAR, ADME, toxicity, clinical and pharmacokinetic properties and biological activities from published patents, journal articles and other public sources.
It also has in-built data analysis and visualization tools for downstream analysis with data export options.
GOSTAR has more than 39 publications from reputed names in the industry citing the usage and utility of the database.
Drug Repurposing (DRx), also known as Drug Repositioning and Drug Re-Profiling is the strategy to identify alternate therapeutic uses for existing compounds, marketed drugs, failed candidates or clinical candidates. It is rapidly emerging as the most preferred route for launching new treatment agent's within a short period of time.
At Excelra, we utilize our proprietary technology, GRIP-Global Repurposing Integrated Platform to help our collaborators in their ongoing R & D efforts to build clinically rich pipeline and provide therapies to patients. We have been able to complete 60+ projects in this space with varied success in experimental validation and moving the assets forward into the clinics.
As opposed to normal drug development, repurposing of existing drugs takes less time and involves lesser cost and resources. Moreover, the repurposed drugs have reduced risk of toxicology and low risk of failure.
DRx strategy offers great potential for the pharma industry to increase the R & D productivity which gets stalled due to drug attrition rate, patent expiry or change in therapeutic strategy to pursue the candidate. Excelra is open to collaborate with partners who are interested in utilizing our platform for various needs and applications.
Accelerate your Translational Discovery efforts
Excelra's Biomarker Discovery Platform (BDPx) combines its proprietary database-GOBIOM, computational biology services and performs data analytics on top of all; in order to provide the optimal solutions to our collaborators.
Right Biomarker for Right Trial/ Accelerate Translational Discovery
In the era of pharmacogenomics and personalized medicine, a lot of data needs to be gathered, analyzed and predicted in order to have a differentiated strategy with a wealth of information present in what is not known yet. Excelra's strengths in big data and predictive analytics allows researchers to go further from the reported biomarkers in the literature with priority on clinical significance.
A Comprehensive Platform to enable your Drug Discovery Research
Excelra has been working with pharma and biotech companies to support their R & D efforts across the drug discovery value chain. Our integrated drug discovery platform constitutes of a combination of our flagship knowledgebases and customized solutions.
Our Drug Discovery Platform (DDPx) has been able to create value for our partners that have led to novel discoveries and help advance the program forward in the pipeline.
Epidemiology, HEOR, and Post-Authorization Studies Services
Excelra Knowledge Solutions Pvt. Ltd. has not received any reviews.
Excelra Knowledge Solutions Pvt. Ltd. has not received any endorsements.